Filter News
Area of Research
News Type
News Topics
- (-) Biomedical (2)
- (-) Materials Science (4)
- 3-D Printing/Advanced Manufacturing (9)
- Advanced Reactors (1)
- Artificial Intelligence (5)
- Big Data (1)
- Bioenergy (6)
- Biology (1)
- Biotechnology (2)
- Buildings (2)
- Chemical Sciences (3)
- Clean Water (1)
- Climate Change (2)
- Composites (2)
- Computer Science (4)
- Coronavirus (2)
- Cybersecurity (5)
- Decarbonization (5)
- Energy Storage (4)
- Environment (4)
- Fusion (1)
- Grid (2)
- High-Performance Computing (2)
- Machine Learning (4)
- Materials (6)
- Microscopy (1)
- Nanotechnology (1)
- National Security (3)
- Net Zero (1)
- Neutron Science (10)
- Nuclear Energy (2)
- Partnerships (7)
- Physics (1)
- Renewable Energy (1)
- Security (3)
- Simulation (1)
- Sustainable Energy (6)
- Transportation (7)
Media Contacts
Four scientists affiliated with ORNL were named Battelle Distinguished Inventors during the lab’s annual Innovation Awards on Dec. 1 in recognition of being granted 14 or more United States patents.
Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.
ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.
Quanex Building Products has signed a non-exclusive agreement to license a method to produce insulating material from ORNL. The low-cost material can be used as an additive to increase thermal insulation performance and improve energy efficiency when applied to a variety of building products.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.